TrialMedicine2018

A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.

Hozumi Kumagai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.